AC Immune SA reports results for the quarter ended in December - Earnings Summary

AC Immune SA

14/03/2024 13:05

* AC Immune SA  ACIU.OQ  reported a quarterly adjusted loss
of 5
rappen​​ per share for the quarter ended in December, higher
than the same quarter last year, when the company reported EPS
of -23 rappen.  The mean expectation of three analysts for the
quarter was for a loss of 11 rappen per share. Wall Street
expected results to range from -22 rappen to -2 rappen per
share.
    * Reported revenue was zero​; analysts expected CHF10.03
million. 
    * AC Immune SA's reported EPS for the quarter was a loss
of 5
rappen​.
    * The company reported a quarterly loss of CHF4.74 million.
    * AC Immune SA shares had fallen by 26.0% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2,098.8% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for AC Immune SA is
$9.00 
This summary was machine generated from LSEG data March 14 at
01:04 p.m. UTC. ​All figures in Swiss francs unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.11          -0.05          Beat
 Sep. 30 2023      0.03           -0.18          Missed
 Jun. 30 2023      -0.20          -0.20          Met
 Mar. 31 2023      -0.23          -0.21          Beat